Elevated plasma fibrinogen: Cause or consequence of cardiovascular disease?

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 18, Issue 4, 1998, Pages 621-625

  Van Der Bom, Johanna G ^a,b,c   De Maat, Moniek P M ^b   Bots, Michiel L ^a,c   Haverkate, Frits ^b   De Jong, P T V M ^a,d,e   Hofman, Albert ^a   Kluft, Cornelis ^b   Grobbee, Diederick E ^a,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d Ophthalmic Research Institute   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

455G A polymorphism; Cardiovascular disease risk; HaeIII polymorphism; Thrombotic tendency; fibrinogen gene

Indexed keywords

FIBRINOGEN;

ACUTE HEART INFARCTION; AGED; ARTICLE; CORONARY RISK; FEMALE; FIBRINOGEN BLOOD LEVEL; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0008029564     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.18.4.621     Document Type: Article

References (21)

1. Kannel WB, Wolf PA, Castelli WP, D'Agostino RBD. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA. 1987;258:1183-1186.
2. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641.
3. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a metaanalysis and review of the literature. Ann Intern Med. 1993;118:956-963.
4. Maat MPM, Knipscheer HC, Kastelein JJP, Kluft C. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidemia. Thromb Haemost. 1997;77:75-79.
5. Behague I, Pionier O, Nicaud V, Evans A, Arveiler D, Luc G, Cambou GP, Scarabin PY, Bara L, Green F, Cambien F. β-Fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. Circulation. 1996;93:440-449.
6. Thomas AE, Green FR, Kelleher CH, Wilkes HC, Brenman PJ, Meade TW, Humphries SE. Variation in the promoter region of the β-fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thromb Haemost. 1991;65:487-490.
7. Scarabin PY, Bara L, Ricard S, Poirier O, Cambou JP, Arveiler D, Luc G, Evans AE, Samama MM, Cambien F. Genetic variation at the β-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. Arterioscler Thromb. 1993;13:886-891.
8. Gardemann A, Schwartz O, Haberbosch W, Katz N, Weisz T, Tillmans H, Hehrlein W, Waas W, Eberbach A. Positive association of the β-fibrinogen H1/H2 gene variation to basal fibrinogen levels and to the increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction. Thromb Haemost. 1997;77:1120-1126.
9. Hofman A, Grobbee DE, de Jong PTVM, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol. 1991;7:403-422.
10. van Bemmel JH, Kors JA, van Herpen G. Methodology of the modular ECG analysis system: MEANS. Methods Inf Med. 1990;29:346-353.
11. Willems JL, Abreu-Lima C, Arnaud P, van Bemmel JH, Brohet C, Degani R, Denis B, Gehring J, van Herpen G, et al. The diagnostic performance of computer programs for the interpretation of electrocardiograms. N Engl J Med. 1991;325:1767-1773.
12. Rose GA, Blackburn H, Gillum RF. Cardiovascular Survey Methods. Geneva, Switzerland: World Heath Organization; 1982.
13. Bots ML, van Swieten JC, Breteler MM, de Jong PTVM, van Gijn J, Hofman A, Grobbee DE. Cerebral white matter lesions and atherosclerosis in the Rotterdam Study. Lancet. 1993;341:1232-1237.
14. van der Bom JG, Bots ML, de Bruijn AM, Hofman A, Grobbee DE. Measurement of β-thromboglobulin in the elderly: findings from the Rotterdam Study. Fibrinolysis. 1994;8(suppl 2):157-159.
15. Ranby M, Sundell IB, Nilsson TK. Blood collected in strong acidic citrate anticoagulant used in a study of dietary influence on basal tPA activity. Thromb Haemost. 1989;62:917-922.
16. Von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957;17:231-237.
17. Krobot K, Hense HW, Cremer P, Eberle E, Keil U. Determinants of plasma fibrinogen: relation to body weight, waist-to-hip ratio, smoking, alcohol, age, and sex: results form the Second MONICA Augsburg Survey, 1989-1990. Arterioscler Thromb. 1992;12:780-788.
18. Folsom AR, Conlan MG, Davis CE, Wu KK. Relations between hemostasis variables and cardiovascular risk indicators in middle aged adults. Ann Epidemiol. 1992;2:481-494.
19. Lee AJ, Lowe GDO, Woodward M, Tunstall-Pedoe H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study. Br Heart J. 1993;69:338-342.
20. Holm B, Nilsen DWT, Kierulf P, Godal HC. Purification and characterization of 3 fibrinogens with different molecular weights obtained from normal human plasma. Thromb Res. 1985;37:165-176.
21. de Maat MPM, Kockx M, Kastelien JJP, Kluft C. Modulation of plasma fibrinogen levels by medication. Fibrinolysis. 1996;10(suppl 4):3. Abstract.